{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["67"],"submitter":["Zhou S"],"funding":["Macau University of Science and Technology"],"pubmed_abstract":["Novel anti-HER2 antibody-drug conjugates trastuzumab deruxtecan (DS-8201a) showed its effect in previously-treated HER2-low metastatic breast cancer, suggesting a promising future in HER2-low breast cancer. We retrospectively reviewed the clinicopathological data of 325 patients with stage I-III HER2 negative breast cancer who received neoadjuvant chemotherapy in the First Affiliated Hospital of Sun Yat-sen University from January 2016 to June 2021. In general, 91 patients (28.0%) were HER2-zero, and 234 patients (72.0%) were HER2-low. The pathological complete response (pCR) rate of the entire cohort was 17.3%. The pCR rate was 16.7% in HER2-low group, and 18.9% in HER2-zero group, showing no significant difference. Patients with HER2-low tumors had significantly longer overall survival ("],"journal":["Breast (Edinburgh, Scotland)"],"pagination":["1-7"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9792954"],"repository":["biostudies-literature"],"pubmed_title":["Comparison of clinicopathological characteristics and response to neoadjuvant chemotherapy between HER2-low and HER2-zero breast cancer."],"pmcid":["PMC9792954"],"pubmed_authors":["Zhou S","Zhen T","Shao N","Lin Y","Liu T","Kuang X","Shi H"],"additional_accession":[]},"is_claimable":false,"name":"Comparison of clinicopathological characteristics and response to neoadjuvant chemotherapy between HER2-low and HER2-zero breast cancer.","description":"Novel anti-HER2 antibody-drug conjugates trastuzumab deruxtecan (DS-8201a) showed its effect in previously-treated HER2-low metastatic breast cancer, suggesting a promising future in HER2-low breast cancer. We retrospectively reviewed the clinicopathological data of 325 patients with stage I-III HER2 negative breast cancer who received neoadjuvant chemotherapy in the First Affiliated Hospital of Sun Yat-sen University from January 2016 to June 2021. In general, 91 patients (28.0%) were HER2-zero, and 234 patients (72.0%) were HER2-low. The pathological complete response (pCR) rate of the entire cohort was 17.3%. The pCR rate was 16.7% in HER2-low group, and 18.9% in HER2-zero group, showing no significant difference. Patients with HER2-low tumors had significantly longer overall survival (","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Feb","modification":"2026-05-31T02:11:48.997Z","creation":"2025-04-04T21:00:57.05Z"},"accession":"S-EPMC9792954","cross_references":{"pubmed":["36535072"],"doi":["10.1016/j.breast.2022.12.006"]}}